The discovery of new-generation TKIs has revolutionized the treatment of patients with CML, although resistance toward BCR-ABL TKIs is still a relevant clinical problem [43,44]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.